Previous studies have identified candidate circulating microRNAs (circmiRs) as biomarkers for heart failure (HF) using relatively insensitive arrays, validated in small cohorts. The present study used RNA sequencing to identify novel candidate circmiRs and compared these with previously identified circmiRs in a large, prospective cohort of patients with acute HF (AHF). 
Introduction
To date, natriuretic peptides are the only circulating biomarkers routinely used in the diagnosis and prognostication of heart failure (HF).
1 Improved HF prognostication may identify patients who might benefit from closer follow-up and from more aggressive treatment. Therefore, the exploration of novel prognostic markers of HF may improve clinical management.
Circulating microRNAs (circmiRs) have been proposed as an attractive new class of biomarkers because of their stability in the circulation, and their ensuing reliable assessment in easily accessible samples. 2 However, most of the studies published to date involve relatively small numbers of HF patients and findings are often discrepant between studies.
3 -7 Larger studies are scarce and have not investigated the temporal patterns of microRNAs (miRs) in patients with HF. 8 Importantly, longitudinal circmiR measurements in HF patients may provide further insight into individual temporal patterns and the patient's ensuing risk for disease progression and adverse outcome.
In the present study, an RNA sequencing discovery experiment in pigs was used to identify circmiRs produced by the myocardium. Subsequently, the potential for prognostication of the most promising novel circmiR (miR-1306-5p) was tested in a set of 475 patients prospectively included for serial sampling after an admission for acute HF (AHF) and compared with multiple miRs known to be cardiac-enriched or previously linked to HF (miR-1254, miR-22-3p, miR-345-5p, miR-378a-3p, miR-423-5p, miR-320a, miR-133a-3p, miR-133b, miR-499a-5p, miR-622 and miR-208a-3p).
Methods

Part I. Preclinical study design Aortic banding and plasma and tissue harvesting
Experiments were performed in aortic banding (AoB)-treated (n = 29) and sham-operated (n = 21) Yorkshire × Landrace swine (details including surgical procedures and sacrifice of the animals are available in the supplementary material online, Appendix S1). Briefly, following thoracotomy, the proximal ascending aorta was dissected free. Bands were placed in AoB animals. 9 Up to 8 weeks later, swine were instrumented for simultaneous arterial and coronary venous blood sampling, followed by excision of the heart and harvesting of myocardial tissue samples from the left ventricular anterior wall.
RNA sequencing
RNA was isolated from myocardial tissue and from arterial and coronary venous plasma samples of AoB-treated (n = 4) and sham-operated (n = 4) swine at 8 weeks after sham and AoB. For subsequent sequencing, RNA was pooled from myocardial tissue samples and from plasma obtained from arterial and coronary venous samples from AoB-treated and sham-operated samples, respectively. Pooled RNA from each sample was then divided in two to allow for two technical replicates per sample. This resulted in a total of 16 samples, which were sent to BGI Shenzhen (Shenzhen, Guangdong, China) for sequencing of small RNAs. At BGI, libraries were prepared using the NEBNext ® Multiplex Small RNA Library Prep Set for Illumina ® Kit (New England Biolabs, Inc., Ipswich, MA, USA NextSeq 500 platform and base-calling was performed using bcl2fastq version 2.0 conversion software from Illumina.
Quality control of fastq files was performed using FASTQC (https:// www.bioinformatics.babraham.ac.uk/projects/fastqc/). Trimmomatic Version 0.32 was used to carry out 3' adapter clipping of reads, using a phred score cut-off of 30 in order to trim low-quality bases whilst ensuring that reads with a length below 18 bases were discarded. 10 
Differential miR expression analysis
Differential expression in the RNA sequencing data was analysed using the R Bioconductor package DESeq2.
11 MicroRNAs were selected based on next-generation sequencing results. Only miRs that were differentially expressed or had a high abundance in heart tissue were analysed. Quantitative polymerase chain reaction (qPCR) was used to analyse expression levels of selected miRs in coronary venous and arterial plasma samples from 21 sham pigs and 29 AoB pigs. Plasma samples were analysed to obtain a trans-coronary gradient in a comparable fashion: sham arterial plasma vs. coronary venous plasma, and AoB arterial plasma vs. coronary venous plasma. Owing to the availability of replicates, the dispersion method 'pooled' from DESeq2 was used to accurately estimate dispersion between each comparison. DESeq2's negative binomial model was used to estimate differentially expressed miRs for each analysis. At the end, only those miRs passing a fold-change (log2) cut-off of 1.0 together with a false discovery rate cut-off of 0.05 were deemed to be significantly differentially expressed.
Part II. Clinical study design
TRIUMPH was an observational, prospective study enrolling patients admitted with AHF in 14 hospitals in the Netherlands, between September 2009 and December 2013. The study was designed to allow the analysis of novel potential biomarkers for prognosis in HF patients, with a particular interest in changes in blood biomarker patterns over time and their prognostic value in HF patients. The study was approved by the medical ethics committees of all participating centres. All patients provided written informed consent.
Patients
Patients were eligible if they were aged ≥18 years and hospitalized for AHF resulting from decompensation of known, chronic HF or newly diagnosed HF, and met all three of the following criteria: (i) natriuretic peptide levels elevated to three or more times the upper limit of normal (determined in each individual hospital); (ii) evidence of sustained left ventricular dysfunction, defined as moderate to poor systolic function or grade II (pseudonormal) to grade IV (fixed restrictive) diastolic dysfunction on echocardiography during hospitalization, and (iii) treatment with i.v. diuretics. Patients were excluded if they suffered from HF precipitated by a non-cardiac condition, by an acute ST elevation myocardial infarction or by severe valvular dysfunction without sustained left ventricular dysfunction. Furthermore, patients were excluded if they were scheduled for coronary revascularization, listed for heart transplantation, suffered from severe renal failure requiring dialysis or had a coexisting condition that implied life expectancy of <1 year.
Patient management
Patient management strategies were selected at the discretion of the treating clinician, in accordance with the guidelines of the European Society of Cardiology. 12 Of note, biomarker data obtained in the context of this study were unknown to the treating physicians and thus were not used in clinical decisions.
Study procedures
Blood samples were obtained from all patients during hospitalization at admission (day 1), once during days 2-4 and subsequently at discharge; thus, three samples per patient were drawn during hospitalization. Additionally, blood samples were obtained at outpatient clinic follow-up visits planned at 2-4 weeks, 3 months, 6 months and 9-12 months after discharge; thus, four samples were drawn during follow-up. Hence, a total of seven samples were obtained for each patient unless that patient was censored or died before all samples could be taken. A short medical evaluation was performed and blood samples were collected at every follow-up visit. Adverse cardiovascular events and changes in medication were recorded on electronic case report forms.
MicroRNA and NT-proBNP measurements
MicroRNAs were measured in all separate plasma samples as described in detail in the supplementary material online, Appendix S1. miR-1254, miR-22-3p, miR-423-5p, miR-320a and miR-622 were selected because they were associated with HF in previous studies, 5,7,13 miR-378a-3p and miR-345-5p because of their enrichment in cardiomyocytes, 14 and miR-133a-3p, miR-133b, miR-208a-3p and miR-499a-5p because they are muscle-specific miRs (so-called 'myomiRs'), of which the latter two are heart-specific and are released during myocardial injury.
15,16
miR-486-5p was used for normalization of the other miRs because endogenous miRs have been shown to carry advantages for normalization compared with spike-in (e.g. Cel39) or small RNAs. 17 In the RNA sequencing experiment, miR-486-5p was observed to be exceptionally abundant (representing the vast majority of all detected miRs in the circulation; see Results) and stable compared with other miRs, making it a suitable candidate to use as a normalizer (details of normalization and NT-proBNP measurements are described in the supplementary material online, Appendix S1).
Quality control of human miR measurements
Polymerase chain reaction of circmiRs is sensitive to false or inaccurate signals, which may result in missing values. 18 Missing values may result from technical errors, but are most often attributable to template levels that are too low to measure reliably with qPCR. Therefore, a quality assessment algorithm was used to ensure the validity of each measurement. This algorithm is described more extensively elsewhere.
19
In brief, three groups of measurements were distinguished: 'detectable'; 'non-detectable' (signal too low), and 'invalid'. If the measurement passed all the quality checks, it was considered to be valid and was marked as 'detectable'. In the event of a 'non-detectable' signal, the measurement was set to a low value, which was based on the PCR experiment parameters. If the measurement did not pass the quality controls of the algorithm, it was defined as 'invalid'. Such measurements were not used in further analyses.
Endpoints
The primary endpoint comprised the composite of all-cause mortality and readmission for HF. The latter was defined as an unplanned rehospitalization for AHF, with at least two of the following three criteria: (i) elevated natriuretic peptide levels of three or more times the upper limit of normal: (ii) symptoms of cardiac decompensation (e.g. rales, oedema or elevated central venous pressure), and (iii) administration of i.v. diuretics. Secondary endpoints included the individual components of the primary endpoint and cardiovascular mortality.
During follow-up, information on vital status and hospital readmissions was obtained until at least 9 months to a maximum of 400 days after the index hospital admission. The investigators approached the civil registry, screened all medical records and asked patients for information during follow-up visits. A clinical event committee blinded to the biomarker results subsequently reviewed all collected information and adjudicated primary and secondary endpoints.
Statistical analysis
The associations between baseline miR measurements and the risk for a study endpoint were assessed using Cox proportional hazard models. Abundant miRs were examined as continuous variables, and less abundant miRs were entered into the models as dichotomous variables (detectable vs. non-detectable, as defined by the algorithm described above). For repeated miR measurements, associations between the current level of each separate miR at a particular time-point and the risk for an endpoint at that same time-point were assessed using a joint modelling approach, which combines a linear mixed-effects model for the repeated miR measurements with a Cox proportional hazards model for the risk for experiencing the event of interest. 20 A detailed description of the statistical analysis is provided in the supplementary material online, Appendix S1.
Results
RNA sequencing in pig samples
Post-quality control, the total number of reads per sample successfully aligned to pig-specific hairpin sequences ranged from 83.7% to 97.3%. Combining all reads together, followed by the discarding of sequences longer than 25 nucleotides and those with low abundance (fewer than four reads per sample) resulted in 373 × 10 6 reads that were successfully mapped to pig hairpin sequences. Aligning unmapped reads to hairpin sequences of other species increased the alignment rate by a negligible fraction (0.46%), suggesting that known hairpin sequences of Sus scrofa were close to complete. Hence, only those sequences that were mapped to S. scrofa hairpins were used.
When the numbers of reads aligned to each hairpin and mature miR sequence were calculated, a high abundance of miR-486-5p was observed in plasma samples (constituting 92.5-97.0% of all reads). There were a number of circmiRs with positive and significant trans-coronary gradients (Figure 1 ). Among these were known myomiRs such as miR-133a. In addition, lesser known circmiRs, such as miR-1306, showed positive gradients. A comparison of next-generation sequencing-based miR expression across tissue samples revealed a total of 16 miRs differentially expressed in sham-operated tissue compared with AoB-treated tissue (Table 1) , among which miR-1306-5p was also significantly up-regulated.
Given the positive trans-coronary gradient of miR-1306-5p and its significant up-regulation in myocardial tissue of AoB compared with Sham pigs, the potential role of miR-1306-5p as a circulating biomarker was further evaluated. The values obtained for shown as the mean ± standard error of the mean (SEM). A negative value indicates release of the microRNA by the myocardium, and a positive value indicates uptake. The P-value is calculated using a paired-samples t-test, and indicates the difference between arterial and venous Ct value of the microRNA.
miR-1306 in the control samples routinely taken on qPCR plates were compared with measurements in HF samples, which showed that levels of circulating miR-1306-5p were significantly higher in HF patients [odds ratio (OR) 1.43, 95% confidence interval (CI) 1.033-1.98 in arbitrary units)/ln (pg/mL); P < 0.05], further increasing the probability that circulating miR-1306-5p may serve as a novel biomarker for HF.
Prospective clinical study: baseline characteristics
A total of 496 patients were enrolled in the TRIUMPH clinical cohort and provided written informed consent. Three patients withdrew their informed consent. Eighteen patients were withdrawn from statistical analyses because of violations of the inclusion protocol. These patients had no evidence of sustained systolic or diastolic left ventricular dysfunction on echocardiography. Accordingly, 475 patients remained. Of these, 456 patients had at least one valid miR-486-5p measurement available, and thus comprised the analysis set. The median age of the patient cohort was 73 years [interquartile range (IQR) 64-80 years], 63% were men and median left ventricular ejection fraction was 30% (IQR 21-42%) ( Table 2 ). Median baseline NT-proBNP level was 4143.7 pg/mL (IQR 2097.5-9053.2 pg/mL).
Clinical endpoints
The composite primary endpoint was reached by 188 patients (41%) during a median follow-up of 325 days (IQR 85-401 days 
Circulating miR measurements
A total of 2214 blood samples were available for the current investigation. The median number of miR measurements per patient was three (IQR 2-5). Supplementary material online, Table S1 displays the number of measurements detectable per miR. miRs that were detectable in fewer than 700 of 2214 samples were not used as continuous variables in further analyses, but were dichotomized (detectable vs. non-detectable) as described above. The miRs that were examined as continuous variables were miR-320a, miR-1254, miR-22-3p, miR-378a-3p, miR-423-5p, miR-345-5p and miR-1306-5p. The miRs dichotomized were miR-133a-3p, miR-133b and miR-499a-5p. miR-486-5p was used for normalization of these miR levels. miR-622 and miR-208a-3p, respectively, were detectable in only 56 and six of 2214 samples. This low expression did not allow for meaningful statistical analysis of these miRs. Additionally, supplementary material online, Table S2 shows the baseline characteristics stratified by invalid vs. valid measurements of baseline miR-1306-5p. Finally, miR expression levels in patients with HF with reduced ejection fraction (HFrEF) vs. HF with preserved ejection fraction (HFpEF) are presented in the supplementary material online, Table S3 . Figure 2 shows the differences in risk for experiencing the primary endpoint for patients in different quartiles of baseline miR-1306-5p levels (P < 0.001). This was confirmed in the subsequently fitted Cox models, in which baseline miR-1306-5p levels were significantly and independently associated with the primary endpoint [hazard ratio (HR) 1.13, 95% CI 1.03-1.23] ( Table 3) . Of the other known miRs, only the baseline levels of miR-320a were significantly and independently associated with the primary endpoint (HR 1.10, 95% CI 1.00-1.21). Associations with secondary endpoints are shown in the supplementary material online, Table S4 . A sensitivity analysis on the subgroup of HFrEF patients rendered an HR for baseline miR-1306-5p in relation to the primary endpoint similar to the HR in the total group, but with a wider CI (HR 1.09, 95% CI 0.95-1.25) (supplementary material online, Table S5 ). This was most likely caused by a decrease in statistical power in this subgroup.
Associations between baseline miR levels and clinical endpoints
Associations between temporal miR patterns and clinical endpoints
Repeatedly measured miR-1306-5p level was positively and independently associated with the primary endpoint (HR CI 2.18-10.06; P < 0.001) ( Table 4 ). The temporal patterns of miR-320a, miR-378a-3p and miR-423-5p were positively associated with the primary endpoint after adjustment for age and sex. However, these associations disappeared after multivariable adjustment. The temporal pattern of miR-1254 displayed a borderline significant association with the primary endpoint after adjustment for age and sex (HR 1.22, 95% CI 1.00-1.50). Associations of temporal patterns with secondary endpoints are shown in the supplementary material online, Table S6 .
Incremental prognostic value of miR-1306-5p
Adding baseline miR-1306-5p to a model containing NT-proBNP, age, sex, systolic blood pressure, diabetes mellitus, atrial fibrillation, body mass index, previous hospitalization for HF during the last 6 months, ischaemic HF, and baseline estimated glomerular filtration rate (eGFR) produced a change in the C-statistic of 0.012 (95% CI − 0.006 to 0.029), a continuous net reclassification improvement (cNRI) of 0.125 (95% CI −0.016 to 0.267), and an integrated discrimination index (IDI) improvement of 0.020 (95% CI −0.013 to 0.053), as shown in the supplementary material online, Table S7 . Thus, the incremental prognostic value of miR-1306-5p on top of NT-proBNP did not reach statistical significance.
Discussion
Direct RNA sequencing of plasma from instrumented pigs revealed a number of circmiRs to be produced by the pig myocardium, including miR-1306-5p, which had not yet been identified as a miR CI, confidence interval; miR, microRNA. Model 1 unadjusted; model 2 adjusted for age and sex; model 3 adjusted for age, sex, systolic blood pressure, diabetes mellitus, atrial fibrillation, body mass index, previous hospitalization for heart failure during the last 6 months, ischaemic heart failure, baseline estimated glomerular filtration rate and baseline NT-proBNP level. Primary endpoint: composite of all-cause mortality and readmission for heart failure. related to the heart. Subsequently, in a prospective AHF cohort, repeatedly assessed circulating miR-1306-5p was found to be positively and independently associated with all-cause mortality and HF hospitalization. This association was independent of NT-proBNP. However, a model containing baseline miR-1306-5p measurements did not significantly improve model discrimination or reclassification in comparison with NT-proBNP. Repeatedly assessed circulating miR-320a, miR-378a-3p, miR-423-5p and miR-1254 were associated with the primary endpoint after adjustment for age and sex . (although this association was borderline for miR-1254), but not after further multivariable adjustment for clinical characteristics. Furthermore, an independent association was found between baseline values of miR-1306-5p and miR-320a and the primary endpoint. Importantly, the current findings are in line with those described in a report on a study conducted in two large cohorts. 35 In these two independent cohorts, miR-1306-5p was also positively and significantly associated with risk for all-cause mortality or HF hospitalization. This further strengthens the present findings and demonstrates for the first time reproducible results on circmiRs across three large cohorts. This contrasts with previous studies, which usually analysed a single, generally smaller cohort 21 and with the fact that previous results have usually been discrepant between studies. To the best of the current authors' knowledge, the association between miR-1306-5p and cardiovascular disease has not been previously investigated and further research on its expected targets is warranted.
RNA sequencing using plasma-derived RNA led to the discovery of miR-1306-5p produced by the heart. Akat et al. also used RNA sequencing to analyse miRs potentially produced by the human heart. 22 However, their study was not designed to assess the clinical value of circmiRs as biomarkers. It should be noted that the large proportion of invalid and undetectable miR-1306-5p measurements reduces power and illustrates the need for more sensitive methods of miR assessment to enable the optimal use of this marker in clinical prognostication. Nevertheless, the current study carried sufficient statistical power to demonstrate a significant association between repeatedly measured miR-1306-5p and the primary and secondary endpoints despite the proportion of invalid and undetectable measurements.
In line with the present results, Bayes-Genis et al. also found an association between miR-1254 and clinical outcome. 35 Other existing data on miR-1254 are limited; of note is the demonstration by Tijsen et al. of the up-regulation of miR-1254 in HF cases compared with healthy controls. 5 An association between higher baseline miR-423-5p levels and signs of progressive HF has been demonstrated in animal models, 6 and human studies with limited sample sizes. 3, 5 Rising miR-423-5p has also been related to worsening left ventricular function and has been shown to be up-regulated in patients with non-ST elevation myocardial infarction. 23 The present results agree with the findings of the aforementioned studies. Conversely, in a recent study in 236 AHF patients, an inverse association was observed between miR-423-5p and hospital readmission. 8 However, this finding could not be reproduced in the validation cohort examined. 8 Smaller studies have previously demonstrated higher circulating levels of miR-320a in HF patients compared with healthy individuals. 7, 24 In addition, rat models have proven that overexpression of miR-320a leads to a greater loss of cardiomyocytes during infarction and that inhibition of miR-320a leads to reduced infarction size. 25 Furthermore, miR-320a showed a protective effect on left ventricular remodelling after myocardial ischaemia-reperfusion injury in a rat model. 26 The results of the current study are in line with these previous studies and further expand the evidence concerning miR-320a by showing that baseline measurements are independently associated with an adverse prognosis in patients with HF, and that repetitively measured miR-320a is independently associated with HF hospitalization in particular. The temporal pattern of miR-378a-3p was also associated with the primary endpoint. Naga Prasad et al. showed down-regulation of miR-378a-3p in left ventricular free wall tissue of HF patients with dilated cardiomyopathy. 4 In contrast, in the current study circulating levels of miR-378a-3p were examined. In addition, Weber et al. found higher levels of circulating miR-378a-3p in five patients with coronary artery disease, compared with five healthy controls. 27 However, other than the current investigation, studies on the prognostic value of miR-378a-3p in patients with HF are lacking.
Repeatedly measured, highly abundant miRs showed only ageand sex-adjusted significant associations with the primary endpoint, and associations disappeared after multivariable adjustment. It is possible that prognostic information provided by these circmiRs, which are probably not produced by the heart, can be easily diluted. Conversely, myomiRs (i.e. miRs that are skeletal and cardiac muscle-specific) carry potential to provide prognostic information that is incremental to clinical characteristics. Such myomiRs play central roles in myogenesis regulation and muscle remodelling. 28, 29 Although the main sources of circulating myomiRs, and particularly the relationship between myomiRs in tissue and plasma, have yet to be fully elucidated, an association between cardiac damage (caused by myocardial infarction or myocarditis) and up-regulation of circulating myomiRs has been previously demonstrated. 15 Moreover, circulating myomiR levels have been associated with skeletal muscle wasting. 30 The current investigation examined several myomiRs (miR-133a-3p, miR-133b, miR-208a-3p and miR-499a-5p). However, myomiRs are expressed in low rates in the circulation, as illustrated by the fact that they were non-detectable in a large proportion of the samples available in the present study. Thus, the current authors were forced to perform a simplified analysis and to examine the association between the presence of detectable myomiR levels at baseline and the occurrence of adverse events. The loss of information inherent to such an analysis may have obscured potential associations with the outcome. Therefore, more sensitive assays are needed to properly examine the roles of myomiRs in HF.
To remove noise by less robust qPCR results, a strict and conservative algorithm was designed and implemented to remove unreliable qPCR data and at the same time to retain reliable assessment of signals that were 'too low to detect'. Furthermore, miR-486-5p was used to normalize the current data because using such endogenous miRs for this purpose has been shown to carry advantages. 17 The quality control algorithm used here has been separately described 19 and the strong concordance across the three large cohorts measured so far supports the suggestion that such algorithms help to remove noise and improve reproducibility.
Some aspects of this study warrant consideration. Firstly, AoB has been used to model HF. This is a model that shows strong similarity to the TAC model in mice and has previously been used in multiple studies as a model for pressure-overload hypertrophy.
31 -34 This model may not be fully representative of human left ventricular dysfunction. However, the current observation that miR-1306-5p, identified in the swine model, does provide prognostic potential in the clinic, underscores the validity of this approach. Secondly, the present analyses were not adjusted for multiple comparisons because the miRs examined were not . selected in a hypothesis-free manner but on the basis of previous fundamental and clinical studies. Nevertheless, if Bonferroni correction were to be applied, the results would remain statistically significant. The association between repeated miR-1306-5p and the primary endpoint rendered an HR of 4.69 (95% CI 2.18-10.06) and a P-value of <0.0001; as seven repeated measurements of miRs were examined, the Bonferroni threshold for the P-value would be 0.05/7 = 0.007. Furthermore, the present study focused on patients with known HF. Studies using a healthy control group may provide insights into temporal miR patterns in healthy persons.
In conclusion, in patients hospitalized for AHF, baseline and repeatedly assessed miR-1306-5p were independently associated with adverse clinical outcome. Associations of temporal patterns of miR-320a, miR-378a-3p, miR-423-5p and miR-1254 with adverse clinical outcomes were not independent of clinical characteristics. Myocyte-specific miRs were non-detectable in a large proportion of samples. More sensitive myomiR assays are needed to allow precise estimations of the risk associated with elevated levels of miRs such as miR-1306-5p, and to investigate whether cardiac-specific myomiRs are capable of providing additional information to established predictors of clinical risk.
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